Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Anacor Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased to $-0.36 in the quarter versus EPS of $-0.47 in the year-earlier quarter.
Revenue: Rose 32.81% to $3.4 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Anacor Pharmaceuticals, Inc. reported adjusted EPS loss of $0.36 per share. By that measure, the company beat the mean analyst estimate of $-0.39. It beat the average revenue estimate of $2.6 million.
Quoting Management: “We had a busy second quarter as we finalized preparations for our NDA for tavaborole, which was submitted on July 26th. This is an exciting time at Anacor as we begin to reap the benefits of the investments that we’ve made in drug development over the last decade and plan the commercialization of our later stage products,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.
Key Stats (on next page)…
Revenue increased 98.83% from $1.71 million in the previous quarter. EPS decreased to $-0.36 in the quarter versus EPS of $-0.42 in the previous quarter.
Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.4 to a loss $0.39. For the current year, the average estimate is a loss of $1.59, which is the same with that ninety days ago.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)